Picard Investment Group Announces Successful Testing Of New Organic Medicinal Product For Shingles and Herpes Simplex Viruses

Using botany to help mitigate the replication of shingles and herpes viruses

PHOENIX - Sept. 29, 2021 - PRLog -- Picard Investment Group, Inc. (Picard) announced today the completion of its eight-year study on shingles (herpes zoster), herpes simplex I and herpes simplex II, called the SH1&2 Project.

Research and testing of its organic product during 2020 and 2021 has determined that the product is effective in mitigating the replication of shingles and herpes simplex I and herpes simplex II viruses, which affect approximately 25 to 40 per cent of the US population. Examples of currently available medications include penicillin, Ciclosporin, Valacyclovir and psilocybin.

"The confirmation of the effectiveness of our organic product has major implications for the healthcare industry," said John Lorenz, director of the SH1&2 project and lifelong herbalist and mycologist who cites renowned mycologists Charles Crossland, Elsie Wakefield, Bill Leigh and Paul Stamets as research inspirations. "It points toward the development of herbal and botany-related products that may be more effective in treating these conditions than originally conceived."

The organic Picard product has been licensed to a US corporation, and will be available for distribution in Q4 2021. Picard is also in licensing discussions with Canadian and European corporations.

# # #

About Picard Investment Group, Inc.
Picard Investment Group, Inc. is an Arizona-based private corporation that specializes in developing organic products for the healthcare sector. It is also active in the waste, restoration, water purification and chemical recycling sectors.

Contact
Cory Lorenz
CAKE Communications
***@cakemedialab.com
Read Full Story - Picard Investment Group Announces Successful Testing Of New Organic Medicinal Product For Shingles and Herpes Simplex Viruses | More news from this source

Press release distribution by PRLog